EUS-Guided Gastroenterostomy Better Option for Cancer-Related Duodenal Blockages
(MedPage Today) -- Using endoscopic ultrasonography-guided gastroenterostomy (EUS-GE) led to better outcomes in the palliation of malignant gastric outlet obstruction compared with conventional stenting of the duodenum, an international randomized... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 8, 2023 Category: Gastroenterology Source Type: news
John Walsh: The Operative Who Paved the Way for Obama ’s 2008 Win
Wash, who died last week at 65 after a battle with stomach cancer, ended up changing American politics with this theory, first upending the Massachusetts political world — and then setting a template for Barack Obama’s presidential win two years later. At the same time, he engendered a new…#massachusetts #barackobama #davidaxelrod #davidplouffe #siliconvalley #devalpatrick #barackobamas #illinois #ussenate #obama (Source: Reuters: Health)
Source: Reuters: Health - December 2, 2023 Category: Consumer Health News Source Type: news
NBC News Correspondent Antonia Hylton Shares Details Of Her Cancer Journey
NBC News correspondent Antonia Hylton has revealed that she was diagnosed with a rare type of cancer, a neuroendocrine tumor. The symptoms manifested about two years ago, the 30-year-old Hylton said in a Today interview. She started having stomach issues. “It was easy for me to just write it off,”…#antoniahylton #hylton #craigmelvins #tiktok (Source: Reuters: Health)
Source: Reuters: Health - December 1, 2023 Category: Consumer Health News Source Type: news
Malpractice dos and don'ts: Primer scoops top RSNA award
The authors of a practical guide designed to help radiologists avoid malpractice claims have received one of 17 magna cum laude awards handed out by the RSNA 2023 judges. Another prizewinner is about imaging of syphilis.
"The majority of radiologists will face litigation in their careers," noted Luke Michael Wojdyla, a second-year radiology resident, and radiologist James Y. Chen, MD, both of UC San Diego Health in California, adding that in a 2021 survey, 71% of radiologists said they had been sued.
"Despite this, dedicated teaching of medicolegal issues is often lacking or incomplete in radiology training programs. Res...
Source: AuntMinnie.com Headlines - November 29, 2023 Category: Radiology Authors: Philip Ward Tags: MRI RSNA 2023 Source Type: news
I thought I had a stomach bug - but it turned out to be cancer: Heartbreak of 41-year-old whose disease has spread through her body
EXCLUSIVE: When Kasia Szczech, who lives in London , started experiencing frequent bouts of sickness after eating last September, she assumed a virus had taken hold. (Source: the Mail online | Health)
Source: the Mail online | Health - November 18, 2023 Category: Consumer Health News Source Type: news
FDA OKs First-Line Pembro With Chemo for Gastric/GEJ Cancer FDA OKs First-Line Pembro With Chemo for Gastric/GEJ Cancer
Adding pembrolizumab to chemotherapy had significant benefits in patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 17, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Merck ’s Keytruda (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval marks seventh gastrointestinal cancer indication for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 16, 2023 Category: Drugs & Pharmacology Source Type: news
FDA approves pembrolizumab with chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma
On November 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 16, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Amends Pembrolizumab Indication in Gastric Cancer FDA Amends Pembrolizumab Indication in Gastric Cancer
The revised indication is based on recent findings from a prespecified interim analysis showing little benefit in patients whose tumors do not express PD-L1.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 9, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Road to RSNA 2023: AI Preview
Welcome to the first installment of this year’s Road to RSNA preview of the RSNA 2023 meeting. We’re once again providing a modality-by-modality overview of select scientific presentations to serve as your guide to events at McCormick Place.
Our journey along the Road to RSNA begins again with our preview of AI, a topic that has dominated the annual meeting for the past seven years. Research on AI topics will be omnipresent, featuring both in dedicated sessions as well as throughout the scientific program. In fact, it’s hard to find a scientific session without at least one AI-related presentation.
AI’s capabilit...
Source: AuntMinnie.com Headlines - November 8, 2023 Category: Radiology Authors: Erik L. Ridley Tags: 2023 Source Type: news
FAPI-PET bests FDG-PET in detecting gastrointestinal cancer
Fibroblast activation protein inhibitor (FAPI)-PET/CT appears superior to standard FDG-PET/CT for detecting gastrointestinal cancer, with higher radiotracer uptake seen in most tumors, according to a study published October 26 in the Journal of Nuclear Medicine. In a clinical trial, researchers in Xiamen, China, compared the two approaches for detecting primary and metastatic tumors in patients with confirmed gastric, liver, or pancreatic cancer.“The use of F-18 FAPI-74 PET/CT is expected to improve the diagnosis of gastrointestinal cancer and contribute to individualized patient care,” wrote senior author Haojun Chen,...
Source: AuntMinnie.com Headlines - October 31, 2023 Category: Radiology Authors: Will Morton Tags: Nuclear Medicine Source Type: news
Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer
(MedPage Today) -- MADRID -- Including pembrolizumab (Keytruda) in the first-line treatment of metastatic HER2-positive gastric or gastroesophageal cancer improved progression-free survival (PFS), but potential harm was seen in PD-L1-negative... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 21, 2023 Category: Hematology Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Basel, 19 October 2023Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecen...
Source: Roche Media News - October 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III...
Source: Roche Investor Update - October 19, 2023 Category: Pharmaceuticals Source Type: news
Merck's Keytruda combo gets EMA panel backing for expanded use in gastric cancer
(Source: Reuters: Health)
Source: Reuters: Health - October 13, 2023 Category: Consumer Health News Source Type: news
